Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855656 · ClinicalTrials.gov registry record · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Debiopharm International.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 464
- Enrollment target
- 20
- Study locations
NCT04855656: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Debiopharm International.
NCT04855656 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 464 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (144% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04855656, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Debiopharm International.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 464 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Primary Outcome
Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements
Conditions Studied
Interventions
- DRUG Lunresertib
- DRUG RP-3500
- DRUG Debio0123
Study Locations (20)
New York
- #1032, Northwell Health Cancer Institute - New Hyde Park
- #1008, Columbia University - New York
- #1004, Memorial Sloan Kettering Cancer Institute - New York
California
- # 1019, UCLA, Westwood Cancer Center - Los Angeles
- #1025, University of California San Francisco - San Francisco
Rhode Island
- #1007, Rhode Island Hospital - Providence
- #1030, Women & Infants Hospital of Rhode Island - Providence
Ontario
- #2002, The Hospital for Sick Children - Toronto
- #2001, Princess Margaret Cancer Centre - Toronto
Connecticut
- #1012, Yale - New Haven
Florida
- #1017, Mayo Clinic - Jacksonville
Massachusetts
- #1002, Dana Farber Cancer Institute - Boston
Michigan
- #1023, START Midwest - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT04855656 shows while recruiting
NCT04855656 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (144% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Lunresertib is the first listed.
NCT04855656 names 20 study sites across 15 states, led by New York, California, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04855656 about?
NCT04855656 is a clinical study titled "Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors". The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
What is the current status of trial NCT04855656?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 464 participants. The study started on 2021-04-30. Estimated completion is 2028-06.
What conditions does trial NCT04855656 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT04855656?
The interventions under investigation include: Lunresertib (DRUG), RP-3500 (DRUG), Debio0123 (DRUG).
Who is sponsoring clinical trial NCT04855656?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04855656 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04855656's enrollment target sits among peer trials
464 13th of 189 higher than 177 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
- NCT07403721 · 464 participants · Phase 1
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI